Continuous glucose monitoring (CGM) Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
22:24
Jan 13
Jan 13
CGM is underpenetrated; GLP-1s are complementary
Leach says CGM has been one of the fastest-growing medtech categories for the past decade, but only 2% of diabetics use it; GLP-1 drugs are complementary because CGM gives immediate feedback and shows GLP-1 benefits, improving adherence, and reimbursement is expanding to all diabetics with 9 million covered U.S. non-users and international access opening in Western Europe and Asia Pacific.
HIGH
About Continuous glucose monitoring (CGM) Investor Commentary
Across the available history and selected sources, Buzzberg tracks Continuous glucose monitoring (CGM) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Jake Leach.